|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BCAS3 |
Gene summary for BCAS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BCAS3 | Gene ID | 54828 |
| Gene name | BCAS3 microtubule associated cell migration factor | |
| Gene Alias | GAOB1 | |
| Cytomap | 17q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q9H6U6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54828 | BCAS3 | CCI_1 | Human | Cervix | CC | 1.48e-10 | 1.07e+00 | 0.528 |
| 54828 | BCAS3 | CCI_2 | Human | Cervix | CC | 3.64e-02 | 4.49e-01 | 0.5249 |
| 54828 | BCAS3 | CCI_3 | Human | Cervix | CC | 9.94e-29 | 1.58e+00 | 0.516 |
| 54828 | BCAS3 | CCII_1 | Human | Cervix | CC | 1.27e-16 | 5.97e-01 | 0.3249 |
| 54828 | BCAS3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.30e-05 | -3.75e-01 | 0.294 |
| 54828 | BCAS3 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.90e-06 | 6.97e-01 | 0.281 |
| 54828 | BCAS3 | A015-C-203 | Human | Colorectum | FAP | 5.74e-20 | -2.60e-01 | -0.1294 |
| 54828 | BCAS3 | A002-C-201 | Human | Colorectum | FAP | 7.84e-06 | -1.01e-01 | 0.0324 |
| 54828 | BCAS3 | A001-C-119 | Human | Colorectum | FAP | 8.87e-03 | 7.74e-05 | -0.1557 |
| 54828 | BCAS3 | A001-C-108 | Human | Colorectum | FAP | 1.11e-06 | 1.60e-02 | -0.0272 |
| 54828 | BCAS3 | A002-C-021 | Human | Colorectum | FAP | 1.30e-04 | 3.39e-01 | 0.1171 |
| 54828 | BCAS3 | A002-C-205 | Human | Colorectum | FAP | 1.24e-19 | -3.45e-01 | -0.1236 |
| 54828 | BCAS3 | A015-C-006 | Human | Colorectum | FAP | 5.16e-15 | -5.11e-01 | -0.0994 |
| 54828 | BCAS3 | A015-C-106 | Human | Colorectum | FAP | 2.50e-04 | 9.28e-03 | -0.0511 |
| 54828 | BCAS3 | A002-C-114 | Human | Colorectum | FAP | 9.26e-17 | -2.80e-01 | -0.1561 |
| 54828 | BCAS3 | A015-C-104 | Human | Colorectum | FAP | 6.25e-22 | -2.60e-01 | -0.1899 |
| 54828 | BCAS3 | A001-C-014 | Human | Colorectum | FAP | 1.05e-05 | -1.35e-02 | 0.0135 |
| 54828 | BCAS3 | A002-C-016 | Human | Colorectum | FAP | 5.25e-16 | -1.83e-01 | 0.0521 |
| 54828 | BCAS3 | A015-C-002 | Human | Colorectum | FAP | 7.09e-10 | -3.31e-01 | -0.0763 |
| 54828 | BCAS3 | A001-C-203 | Human | Colorectum | FAP | 1.66e-04 | -3.66e-03 | -0.0481 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
| GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
| GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
| GO:00019528 | Cervix | CC | regulation of cell-matrix adhesion | 40/2311 | 128/18723 | 1.32e-08 | 1.04e-06 | 40 |
| GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00106349 | Cervix | CC | positive regulation of epithelial cell migration | 47/2311 | 176/18723 | 1.73e-07 | 8.01e-06 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BCAS3 | SNV | Missense_Mutation | novel | c.410N>G | p.Gln137Arg | p.Q137R | Q9H6U6 | protein_coding | tolerated(0.27) | benign(0.093) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BCAS3 | SNV | Missense_Mutation | rs755073133 | c.68N>A | p.Arg23His | p.R23H | Q9H6U6 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| BCAS3 | SNV | Missense_Mutation | c.2038N>A | p.Asp680Asn | p.D680N | Q9H6U6 | protein_coding | tolerated(0.07) | benign(0.073) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| BCAS3 | SNV | Missense_Mutation | novel | c.1331N>C | p.Arg444Pro | p.R444P | Q9H6U6 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-HN-A2OB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
| BCAS3 | insertion | Frame_Shift_Ins | novel | c.2016_2017insTGGAATCATATAATATGTGACCTTTTGTGTCTGG | p.His673TrpfsTer52 | p.H673Wfs*52 | Q9H6U6 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| BCAS3 | SNV | Missense_Mutation | novel | c.2335N>A | p.Asp779Asn | p.D779N | Q9H6U6 | protein_coding | tolerated(0.09) | possibly_damaging(0.642) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BCAS3 | SNV | Missense_Mutation | rs759264893 | c.2318N>T | p.Thr773Met | p.T773M | Q9H6U6 | protein_coding | deleterious(0.02) | benign(0.401) | TCGA-C5-A1BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| BCAS3 | SNV | Missense_Mutation | novel | c.2158G>A | p.Glu720Lys | p.E720K | Q9H6U6 | protein_coding | deleterious(0.01) | possibly_damaging(0.879) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| BCAS3 | SNV | Missense_Mutation | c.1755N>A | p.Phe585Leu | p.F585L | Q9H6U6 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-4N-A93T-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | SD | |
| BCAS3 | SNV | Missense_Mutation | rs377752373 | c.583N>T | p.Arg195Trp | p.R195W | Q9H6U6 | protein_coding | deleterious(0) | possibly_damaging(0.736) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |